B-cell acute lymphoblastic leukemia (B-ALL) with the MLL-AF4 fusion gene has a poor prognosis, and the mortality rate exceeds 90%, particularly in cases of extramedullary relapse (EMR). This evidence concerns the gene KMT2A and precursor B-cell acute lymphoblastic leukemia.